Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Fabrinet — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.8 (market cap $4.59B), while Fabrinet trades at $487.61 (market cap $17.46B). The key difference: Fabrinet is far larger — about 3.8× Definium Therapeutics Inc. Common Shares's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Fabrinet for 30 Days on average.
| DFTX | FN | |
|---|---|---|
Market Cap | $4.59B | $17.46B |
Volume | 2,103,937 | 1,199,886 |
Sector | Health | Technology |
52-Week High | $48.45 | $746.47 |
52-Week Low | $10.68 | $361.94 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $3.55B | $16.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Fabrinet (FN) trades at $493.25, down 0.95% amid mixed technical signals with bullish moving averages but overbought RSI readings. The company demonstrates strong fundamental performance with 45% Q4 revenue growth and consistent earnings beats, driven by surging AI data center demand. Analyst consensus remains strongly bullish with a $769.50 price target representing 56% upside potential, though the stock faces near-term pressure from high capital expenditures.
Fabrinet's AI infrastructure positioning and capacity expansion support long-term growth prospects, but investors should monitor customer concentration risks and margin pressures. The stock's premium valuation (P/E 37.34) requires continued execution on growth targets to justify current levels amid competitive optical component market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
